The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Denali Therapeutics Inc(NASDAQ:DNLI) 
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials...
Website: http://www.denalitherapeutics.com
Founded: 2013
Full Time Employees: 281
Sector: Healthcare
Industry: Biotechnology
Denali Therapeutics Days Payable Outstanding ttm (DPO)
Denali Therapeutics Days Receivable Outstanding ttm (DSO)
Denali Therapeutics Op Cashflow Per Share ttm
Denali Therapeutics Free Cashflow Per Share ttm
Denali Therapeutics Cash Per Share ttm
Denali Therapeutics P/S ratio ttm
Denali Therapeutics (GAAP) P/E ratio ttm
Denali Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.